Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share
Hemostemix (OTCQB:HMTXF), a leading autologous stem cell therapy company, has received TSXV approval to settle CDN$400,000 of debt through the issuance of 2,000,000 common shares at $0.20 per share.
The Settlement Shares will be subject to a four-month statutory hold period and require TSXV acceptance. The company confirms this debt settlement will not create a new control person, and no finder's fees will be paid. Hemostemix offers VesCell™ (ACP-01) therapy in Florida under SB 1768 for various cardiovascular and ischemic conditions.
Hemostemix (OTCQB:HMTXF), azienda leader nelle terapie autologhe con cellule staminali, ha ottenuto l'approvazione della TSXV per estinguere CDN$400.000 di debito mediante l'emissione di 2.000.000 azioni ordinarie a $0,20 per azione.
Le Azioni di Compensazione saranno soggette a un periodo di blocco statutario di quattro mesi e necessitano dell'accettazione della TSXV. La società conferma che questo accordo di ristrutturazione del debito non darà luogo a una nuova persona di controllo e che non saranno pagate commissioni di intermediazione. Hemostemix offre la terapia VesCell™ (ACP-01) in Florida ai sensi della SB 1768 per varie patologie cardiovascolari e ischemiche.
Hemostemix (OTCQB:HMTXF), una empresa líder en terapias autólogas con células madre, ha recibido la aprobación de la TSXV para saldar CDN$400,000 de deuda mediante la emisión de 2,000,000 de acciones ordinarias a $0.20 por acción.
Las Acciones de Liquidación estarán sujetas a un periodo de retención estatutario de cuatro meses y requieren la aceptación de la TSXV. La compañía confirma que este acuerdo de deuda no creará una nueva persona de control y que no se pagarán comisiones de intermediación. Hemostemix ofrece la terapia VesCell™ (ACP-01) en Florida bajo la SB 1768 para diversas afecciones cardiovasculares e isquémicas.
Hemostemix (OTCQB:HMTXF), 자가유래 줄기세포 치료 분야의 선도 기업이 TSXV의 승인을 얻어 CDN$400,000의 부채를 주당 $0.20에 2,000,000 보통주
해결 주식은 4개월의 법정 보호(보유) 기간이 적용되며 TSXV의 승인을 필요로 합니다. 회사는 이번 채무 정리가 새로운 지배주주(통제권자)를 발생시키지 않으며, 소개 수수료(파인더 수수료)는 지급되지 않을 것이라고 확인했습니다. Hemostemix는 플로리다에서 SB 1768에 따라 다양한 심혈관 및 허혈성 질환에 대해 VesCell™(ACP-01) 치료를 제공하고 있습니다.
Hemostemix (OTCQB:HMTXF), société leader dans les thérapies autologues par cellules souches, a obtenu l'approbation de la TSXV pour régler CDN$400,000 de dettes par l'émission de 2,000,000 d'actions ordinaires à $0.20 par action.
Les Actions de Règlement seront soumises à une période de blocage statutaire de quatre mois et requièrent l'acceptation de la TSXV. La société confirme que ce règlement de dette ne créera pas une nouvelle personne de contrôle et qu'aucune commission d'apporteur ne sera versée. Hemostemix propose la thérapie VesCell™ (ACP-01) en Floride en vertu de la SB 1768 pour diverses affections cardiovasculaires et ischémiques.
Hemostemix (OTCQB:HMTXF), ein führendes Unternehmen für autologe Stammzelltherapien, hat die Genehmigung der TSXV erhalten, CDN$400.000 an Schulden durch die Ausgabe von 2.000.000 Stammaktien zu $0,20 pro Aktie zu begleichen.
Die Abrechnungsaktien unterliegen einer gesetzlich vorgeschriebenen Sperrfrist von vier Monaten und bedürfen der Annahme durch die TSXV. Das Unternehmen bestätigt, dass diese Schuldentilgung keine neue Kontrollperson schaffen wird und dass keine Findergebühren gezahlt werden. Hemostemix bietet in Florida gemäß SB 1768 die VesCell™-Therapie (ACP-01) für verschiedene kardiovaskuläre und ischämische Erkrankungen an.
- Company reduces CDN$400,000 of debt obligations
- Debt settlement at $0.20 per share preserves cash resources
- No finder's fees required for the transaction
- Dilution of existing shareholders through issuance of 2,000,000 new shares
Calgary, Alberta--(Newsfile Corp. - September 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, announces that it has entered into agreements to settle an aggregate of CDN
(the "Debt Settlement").
Pursuant to the Debt Settlement, the Company will issue an aggregate of 2,000,000 common shares
(the "Settlement Shares") at a deemed price of
The Debt Settlement is subject to acceptance by the TSX Venture Exchange and will be completed pursuant to TSXV Policy 4.3 (Shares for Debt).
The Debt Settlement will not result in the creation of a new control person. No finder's fees will be paid in connection with the Debt Settlement.
ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of
For further information, please contact:
Thomas Smeenk,
President, CEO & Co-Founder
EM: tsmeenk@hemostemix.com / PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the financing of the Company related to the commercialization of ACP-01. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265944
FAQ
What is the value of Hemostemix's (HMTXF) debt settlement announced on September 10, 2025?
How many new shares will Hemostemix (HMTXF) issue for the debt settlement?
What is the hold period for Hemostemix's (HMTXF) Settlement Shares?
Will the Hemostemix (HMTXF) debt settlement create a new control person?
What treatments does Hemostemix (HMTXF) offer in Florida?
